Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

Stephen Crowe

Group Financial Controller

A commercial, growth-focused and highly experienced Finance Leader with over 20+ years of experience in a wide range of financial institutions from blue chip organizations such as AXA to owner managed SME’s such as THB Group, R K Carvill & Co. and Towergate Partnership. A qualified chartered accountant by profession with a degree from Auckland University (NZ). Most recently have undertaken a number of interim roles within financial services for a number of high growth tech enabled SME’s, before which worked at Source for 6 years a European ETP provider (Investment Manager) which was sold to Invesco in 2017.

Stephen Crowe - NetScientific